Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tunlametinib in NRAS Mutant Advanced Melanoma
NCT03973151Phase 2Completed
- Sponsor
- Shanghai KeChow Pharmaceuticals
- Start
- Sep 2017
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tunlametinib in melanoma, sponsored by Shanghai KeChow Pharmaceuticals. Started Sep 2017; status: completed.
02
Drugs
tunlametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03973151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03973151.